First and only steerable delivery system designed to help seal the left atrial appendage (LAA) in people with atrial fibrillation who are at an increased risk of stroke Now available in the U.S., ...

ABBOTT PARK, Ill., Aug. 30, 2021 /PRNewswire/ -- Abbott (NYSE: ABT) today announced late-breaking data from the Amulet™ LAA Occluder IDE trial, a multi-center, head-to-head study comparing the company ...

New Guidelines Issued for Management of Atrial Fibrillation The Amulet device is designed for complete immediate closure of the left atrial appendage using dual-seal technology. Using dual-seal ...

Valve-in-Valve TAVR for the Failing Surgical Perceval Valve: How to Do It - Tips and Tricks Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Rates of patency and device-related thrombus were ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. BOSTON — At 3 years, the Amplatzer Amulet device ...

SAN FRANCISCO -- Two mainstream devices for percutaneous left atrial appendage (LAA) closure continued to lead to similar clinical outcomes in the SWISS-APERO trial. Among patients randomized to the ...

Within the last 24 months, I have financial relationship(s) or affiliation(s) with a manufacturer, marketer, reseller, or distributor of a healthcare product or service involved in the management of ...

The Amplatzer Amulet (Abbott) and first-generation Watchman 2.5 (Boston Scientific) devices provide relatively comparable results out to 3 years after left atrial appendage occlusion (LAAO), longer ...

Abbott's Amplatzer Amulet provided superior left atrial appendage (LAA) closure over the old-guard Watchman (Boston Scientific) device but failed to significantly cut stroke or bleeding rates in ...